Secondary analyses of the randomized phase III Stop&Go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer
暂无分享,去创建一个
V. Tjan-Heijnen | F. Erdkamp | M. Bos | M. López-Yurda | H. de Graaf | J. Rademaker-Lakhai | A. Honkoop | A. K. M. Claessens | J. Bouma | M. Lopez-Yurda